Men Osteoporosis treatment

Men Osteoporosis treatment. Men lose bone density just as women do. Usually their bone loss it starts later in life than it does for women but if there are certain causes at work men can begin to experience excessive bone loss at an early age. Read: Causes of bone loss.

One of the problems physicians and their male clients experience is that there are fewer studies devoted to Men Osteoporosis treatment than there are studies that concern the treatment of women. However, this is beginning to change.

Here is a report from Japan of a study comparing the effects of two pharmaceuticals: Alendronate and Alfacalcidol (drug form of Vitamin D).

Japanese Men Osteoprosis treatment

Comparison of the Effects of Alendronate and Alfacalcidol on Hip Bone Mineral Density and Bone Turnover in Japanese Men Having Osteoporosis or Osteopenia with Clinical Risk Factors for Fractures. by Jun Iwamoto,corresponding author1 Yoshihiro Sato,2 Mitsuyoshi Uzawa,3 Tsuyoshi Takeda,1 and Hideo Matsumoto1

Purpose of the study:The comparative effects of alendronate and alfacalcidol on bone mineral density (BMD) and bone turnover have already been established in postmenopausal women with osteoporosis. An open-labeled prospective study was conducted to compare the treatment effects of alendronate and alfacalcidol on hip BMD and bone turnover in Japanese men with osteoporosis or osteopenia with clinical risk factors for fractures.

Materials and Methods One hundred twelve men with osteoporosis or osteopenia with clinical risk factors for fractures (mean age: 71.4 years) were randomly divided into two groups of 56 patients each: the alendronate (5 mg daily) and alfacalcidol (1 µg daily) groups. The BMD of the total hip, urinary level of cross-linked N-terminal telopeptides of type I collagen (NTX), and serum levels of bone-specific alkaline phosphatase (BSAP) were measured during the 12-month-treatment period.

Results

Forty-five patients in the alendronate group and 42 patients in the alfacalcidol group completed the trial. Alendronate increased BMD (+2.3% at 12 months) following reductions in the urinary level of NTX (-46.4% at 3 months) and serum level of BSAP (-34.1% at 12 months), while alfacalcidol sustained BMD (-1.9% at 12 months) as well as the urinary level of NTX (+13.2% at 3 months) and serum level of BSAP (+1.8% at 12 months).

Conclusion Thee present study confirmed that alendronate has better efficacy than alfacalcidol (active control) in increasing hip BMD and reducing bone turnover in Japanese men with osteoporosis or osteopenia with clinical risk factors for fractures.

Read more about Men Osteoporosis treatment

Over the last few years I have tried to seek out studies concerning Men and Osteopenia, Osteoporosis. Of course a man can use many of the natural treatments and pharmaceuticals studied for women but there are some unique issues that men face when dealing with bone loss.

Here are some pages about Men Osteoporosis treatment , causes and possible natural remedies you might want to read:

Go to

Causes of Osteopenia and Osteoporosis

Alternative medicine and Natural treatments